Zevra Therapeutics (NASDAQ:ZVRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market [Seeking Alpha]
Zevra Therapeutics (NASDAQ:ZVRA) was given a new $26.00 price target on by analysts at HC Wainwright.
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)